Add Yahoo as a preferred source to see more of our stories on Google. LONDON (Reuters) - Circassia Pharmaceuticals (CIRCI.L), a British company developing allergy therapies, said on Friday it had ...
The UK biotech company is putting its huge failure in allergy treatment behind it with a new deal with AstraZeneca (AZ). But British venture capital leader David Grainger is highly critical of the ...
The most recent earnings announcement Circassia Pharmaceuticals Plc’s (LSE:CIR) released in December 2017 indicated that losses became smaller relative to the prrior year’s level – great news for ...
Steve Harris became the CEO of Circassia Pharmaceuticals plc (LON:CIR) in 2006. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider ...
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune® cat allergy treatment for cat ...
OXFORD, England, September 11, 2012--Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann ...
UK biotech Circassia has had two key decisions go in its favour with FDA, as the company continues with its efforts to rebuild its business after a series of disastrous allergy drug trial failures.
OXFORD, England, January 19 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell ...
- Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ...
LONDON (Reuters) - Britain's Circassia Pharmaceuticals (CIRCI.L) is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader ...
With the business potentially at an important milestone, we thought we'd take a closer look at Circassia Group Plc's (LON:CIR) future prospects. Circassia Group Plc, a medical device company, focuses ...
LONDON (Reuters) - Circassia Pharmaceuticals, a British company developing allergy therapies, said on Friday it had agreed to buy Sweden's Aerocrine and privately held Prosonix, two companies focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results